Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alok Chaturvedi

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Health and Technology|March 29, 2020
Securing the food supply chain: understanding complex interdependence through agent-based simulationAlok Chaturvedi, Brian Armstrong, Rashmi Chaturvedi
Health Care Management Science|December 14, 2007
Simulation tools for developing policies for complex systems: modeling the health and safety of refugee communitiesJames Anderson, Alok Chaturvedi, Mike Cibulskis
Ophthalmology and Therapy|December 29, 2019
A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World's First Biosimilar Ranibizumab) in Wet Age-Related Macular DegenerationShashikant Sharma, Mujtaba Khan, Alok Chaturvedi, et al.
Ophthalmology and Therapy|July 4, 2020
A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein OcclusionShashikant Sharma, , Mujtaba Khan, et al.
Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde|June 27, 2018
Real-Life Clinical Effectiveness of Razumab® (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT StudyShashikant Sharma, Mujtaba A Khan, Alok Chaturvedi, et al.
Expert Opinion on Drug Delivery|June 29, 2019
Letter to the editor: 'current advances in development of new docetaxel formulations'Mujtaba A Khan, Nisarg Joshi, Alok Chaturvedi, et al.
Frontiers in Nephrology|June 24, 2026
Comparative bioequivalence of 1 mg and 4 mg tacrolimus extended-release tablets: randomized, open label, fully replicate, crossover trials in healthy adult subjectsJay Kumar Sharma, Deepak Bunger, Hemant Zaveri, et al.
Molecular and Clinical Oncology|October 29, 2025
Effective management of a diabetic patient with hormone-receptor-positive, HER2-negative metastatic breast cancer using nanosomal docetaxel lipid suspension for 12 cycles: A case reportPrasanna Rammohan, Lav Patel, Deepak Bunger, et al.
Ophthalmology and Therapy|June 22, 2021
Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive ReviewShashikant Sharma, Tanishq Sharma, Somdutt Prasad, et al.
Oncotargets and Therapy|April 10, 2023
Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast CancerRevathi Badiginchala, Palanki Satya Dattatreya, Attili Venkata Satya Suresh, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Health and Technology|March 29, 2020
Securing the food supply chain: understanding complex interdependence through agent-based simulationAlok Chaturvedi, Brian Armstrong, Rashmi Chaturvedi
Health Care Management Science|December 14, 2007
Simulation tools for developing policies for complex systems: modeling the health and safety of refugee communitiesJames Anderson, Alok Chaturvedi, Mike Cibulskis
Ophthalmology and Therapy|December 29, 2019
A Multicenter, Retrospective Study (RE-ENACT 2) on the Use of Razumab™ (World's First Biosimilar Ranibizumab) in Wet Age-Related Macular DegenerationShashikant Sharma, Mujtaba Khan, Alok Chaturvedi, et al.
Ophthalmology and Therapy|July 4, 2020
A Multicenter, Retrospective Study (RE-ENACT 2) on Razumab™ (World's First Biosimilar Ranibizumab) in Retinal Vein OcclusionShashikant Sharma, , Mujtaba Khan, et al.
Ophthalmologica. Journal International D'Ophtalmologie. International Journal of Ophthalmology. Zeitschrift Fur Augenheilkunde|June 27, 2018
Real-Life Clinical Effectiveness of Razumab® (the World's First Biosimilar of Ranibizumab) in Retinal Vein Occlusion: A Subgroup Analysis of the Pooled Retrospective RE-ENACT StudyShashikant Sharma, Mujtaba A Khan, Alok Chaturvedi, et al.
Expert Opinion on Drug Delivery|June 29, 2019
Letter to the editor: 'current advances in development of new docetaxel formulations'Mujtaba A Khan, Nisarg Joshi, Alok Chaturvedi, et al.
Frontiers in Nephrology|June 24, 2026
Comparative bioequivalence of 1 mg and 4 mg tacrolimus extended-release tablets: randomized, open label, fully replicate, crossover trials in healthy adult subjectsJay Kumar Sharma, Deepak Bunger, Hemant Zaveri, et al.
Molecular and Clinical Oncology|October 29, 2025
Effective management of a diabetic patient with hormone-receptor-positive, HER2-negative metastatic breast cancer using nanosomal docetaxel lipid suspension for 12 cycles: A case reportPrasanna Rammohan, Lav Patel, Deepak Bunger, et al.
Ophthalmology and Therapy|June 22, 2021
Treatment Landscape of Macular Disorders in Indian Patients with the Advent of Razumab™ (World's First Biosimilar Ranibizumab): A Comprehensive ReviewShashikant Sharma, Tanishq Sharma, Somdutt Prasad, et al.
Oncotargets and Therapy|April 10, 2023
Efficacy and Safety of Nanosomal Docetaxel Lipid Suspension (NDLS) versus Conventional Docetaxel as Neoadjuvant and Adjuvant Therapy for Primary Operable Breast CancerRevathi Badiginchala, Palanki Satya Dattatreya, Attili Venkata Satya Suresh, et al.
Pageof 2